In a deal that underscores growing interest in cancer immunotherapy, Bristol-Myers Squibb Company (BMS) has agreed to pay $35 million upfront for rights to an early-stage monoclonal antibody that targets receptors on cells of the innate immune system. The developer of the antibody is Innate Pharma SA of Marseilles, France.
